Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 2, Issue 2, 2010, Pages

  Inoue, Daichi ^a   Maruoka, Hayato ^a   Takahashi, Takayuki ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

EID: 79952806232     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2010.020     Document Type: Article

References (29)

1. Lowenberg, B., Griffin, J.D., & Tallman, M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003;82-101.
2. Lo-Coco, F. & Ammatuna, E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 2006;156-161, 514.
3. Reiter, A., Lengfelder, E., & Grimwade, D. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol 2004;112:55-67.
4. Yin, J.A. & Grimwade, D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002;360:160-162.
5. Freeman, S.D., Jovanovic, J.V., & Grimwade, D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008;35:388-400.
6. Miyamoto, T., Weissman, I.L., & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000;97:7521-7526.
7. Al-Mawali, A., Gillis, D., & Lewis, I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009;131:16-26.
8. Coustan-Smith, E., Ribeiro, R.C., Rubnitz, J.E., Razzouk, B.I., Pui, C.H., Pounds, S., Andreansky, M., Behm, F.G., Raimondi, S.C., Shurtleff, S.A., Downing, J.R., & Campana, D. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-252.
9. Feller, N., van der Pol, M.A., van Stijn, A., Weijers, G.W., Westra, A.H., Evertse, B.W., Ossenkoppele, G.J., & Schuurhuis, G.J. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004;18:1380-1390.
10. Kern, W., Voskova, D., Schoch, C., Hiddemann, W., Schnittger, S., & Haferlach, T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078-3085.
11. San Miguel, J.F., Vidriales, M.B., Lopez-Berges, C., Diaz-Mediavilla, J., Gutierrez, N., Canizo, C., Ramos, F., Calmuntia, M.J., Perez, J.J., Gonzalez, M., & Orfao, A. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746-1751.
12. Sievers, E.L., Lange, B.J., Alonzo, T.A., Gerbing, R.B., Bernstein, I.D., Smith, F.O., Arceci, R.J., Woods, W.G., & Loken, M.R. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-3406.
13. Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M., & Amadori, S. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948-3952.
14. Buccisano, F., Maurillo, L., Gattei, V., Del Poeta, G., Del Principe, M.I., Cox, M.C., Panetta, P., Consalvo, M.I., Mazzone, C., Neri, B., Ottaviani, L., Fraboni, D., Tamburini, A., Lo-Coco, F., Amadori, S., & Venditti, A. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006;20:1783-1789.
15. Maurillo, L., Buccisano, F., Del Principe, M.I., Del Poeta, G., Spagnoli, A., Panetta, P., Ammatuna, E., Neri, B., Ottaviani, L., Sarlo, C., Venditti, D., Quaresima, M., Cerretti, R., Rizzo, M., de Fabritiis, P., Lo Coco, F., Arcese, W., Amadori, S., & Venditti, A. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944-4951.
16. Venditti, A., Tamburini, A., Buccisano, F., Del Poeta, G., Maurillo, L., Panetta, P., Scornajenghi, K.A., Cox, C., & Amadori, S. Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. J Hematother Stem Cell Res 2002;11:349-357.
17. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R., & Bloomfield, C.D. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
18. Ackerstein, A., Kedar, E., & Slavin, S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991;78:1212-1215.
19. Al-Mawali, A., Gillis, D., Hissaria, P., & Lewis, I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific fivecolor multiparameter flow cytometry. Am J Clin Pathol 2008;129:934-945.
20. Al-Mawali, A., Gillis, D., & Lewis, I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 2009;76:91-101.
21. San Miguel, J.F., Martinez, A., Macedo, A., Vidriales, M.B., Lopez-Berges, C., Gonzalez, M., Caballero, D., Garcia-Marcos, M.A., Ramos, F., Fernandez-Calvo, J., Calmuntia, M.J., Diaz-Mediavilla, J., & Orfao, A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-2470.
22. Campana, D. & Coustan-Smith, E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139-152.
23. Gorello, P., Cazzaniga, G., Alberti, F., Dell'Oro, M.G., Gottardi, E., Specchia, G., Roti, G., Rosati, R., Martelli, M.F., Diverio, D., Lo Coco, F., Biondi, A., Saglio, G., Mecucci, C., & Falini, B. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103-1108.
24. Chou, W.C., Tang, J.L., Wu, S.J., Tsay, W., Yao, M., Huang, S.Y., Huang, K.C., Chen, C.Y., Huang, C.F., & Tien, H.F. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007;21:998-1004.
25. Papadaki, C., Dufour, A., Seibl, M., Schneider, S., Bohlander, S.K., Zellmeier, E., Mellert, G., Hiddemann, W., & Spiekermann, K. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517-523.
26. Barragan, E., Pajuelo, J.C., Ballester, S., Fuster, O., Cervera, J., Moscardo, F., Senent, L., Such, E., Sanz, M.A., & Bolufer, P. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta 2008;395:120-123.
27. Lapillonne, H., Renneville, A., Auvrignon, A., Flamant, C., Blaise, A., Perot, C., Lai, J.L., Ballerini, P., Mazingue, F., Fasola, S., Dehee, A., Bellman, F., Adam, M., Labopin, M., Douay, L., Leverger, G., Preudhomme, C., & Landman-Parker, J. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24:1507-1515.
28. Steinbach, D., Schramm, A., Eggert, A., Onda, M., Dawczynski, K., Rump, A., Pastan, I., Wittig, S., Pfaffendorf, N., Voigt, A., Zintl, F., & Gruhn, B. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006;12:2434-2441.
29. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G., & Martelli, M.F. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266.